Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01606579
Title Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Prism Pharma Co., Ltd.

bone marrow cancer

chronic myeloid leukemia

acute myeloid leukemia


Cytarabine + PRI-724

Dasatinib + PRI-724


Age Groups: adult
Covered Countries USA

No variant requirements are available.